Mithra FIRST LOOK: Mayne Pharma's 1H24 results
Mithra's commercial partner in the US, Mayne Pharma, reported its 1H24 results for the period Jul-Dec '23. Nextstellis sales were up 94% vs. 2H23, and reached USD 13.8m, driven by a 33% increase in cycles and an improved net selling price. Although the revenue trend turns positive, it will likely not move the needle for Mithra in a major way in the context of its current cash runway. We expect to see more detail in next week's FY23 update.Mithra Pharmaceuticals SA is a Belgium-based company active in the pharmaceutical industry. The Company is dedicated to provide products and services for the fertility, contraception and menopause of women. It has a number of patent families regarding Estetrol (E4), a natural estrogen produced by the human foetus, which enables the investigation of fertility and contraception products. Mithra is focused on the development of two late-stage E4-based products: Estelle, a 5th generation oral contraceptive, and Donesta, a hormone therapy for Vasomotor Symptoms in menopause. Mithra develops a contraceptive vaginal ring called Myring and Zoreline, a biodegradable subcutaneous implant for hormone dependant cancer.
We are a financial services provider for several types of professional clients, each with distinct needs.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.